1 Day
المصدر:
The New York Times
FDA Approves Daraxonrasib for Pancreatic Cancer
A clinical trial found that patients receiving daraxonrasib lived twice as long as those treated with chemotherapy.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading